Infant Reflux Trial: study protocol for a multicentre randomized controlled trial on the treatment of gastroesophageal reflux disease in infants.

Save

Background

Gastroesophageal reflux disease (GERD) is a common condition in infants below 1 year of age. Symptoms include frequent regurgitation, failure to thrive, food refusal, irritability, and back arching. While many infants experience some degree of physiological reflux, persistent or severe symptoms may indicate GERD.

One important underlying cause of GERD in infants is allergy to cow’s milk protein. Current international guidelines recommend a trial of a cow’s milk protein-free diet prior to initiating medical therapy with a proton-pump inhibitor. However, the efficacy of both the diet and the medication remains insufficiently studied.

With only a few randomized trials available, further evidence is needed to ensure infants receive the most appropriate treatment.

Methods

This protocol describes a multicentre, randomized placebo-controlled trial, enrolling 96 infants with a clinical diagnosis of GERD at 3 paediatric centres in Southern Denmark. Eligible participants will be randomly assigned to one of three parallel groups: (1) A diet group receiving a cow’s milk protein-free diet, (2) a medicine group treated with a proton-pump inhibitor, and (3) a control group receiving a placebo medicine. Both the PPI group and the control group will be blinded to the allocation and will continue a diet containing cow’s milk protein.

The intervention period is 4 weeks. The primary outcome is the reduction in the number of regurgitation episodes. Secondary outcomes include weight gain and reduction in GERD-related symptoms.

Symptom data will be reported by parents using a digital application, and specific IgE to cow’s milk protein will be quantified in all participants. Infants in the diet group who respond positively will undergo an oral milk challenge to confirm allergy to cow’s milk protein.

Discussion

This trial is designed to provide evidence on the efficacy of a cow’s milk protein-free diet and proton-pump inhibitor therapy for infant GERD. Both interventions are evaluated against a control group, ensuring that any improvement exceeds the natural course of symptom resolution over time. The findings will provide valuable insights to guide clinical practice and enhance treatment strategies for infant GERD, a condition with a substantial impact on infant health and family well-being.

Prospective trial registration

ClinicalTrials.gov NCT06255886. Registered on February 13, 2024.

ClinicalTrials.eu EU-CT: 2022-502770-16-00. Registered on November 4, 2024.

Administrative information

Note: The numbers in curly brackets in this protocol refer to SPIRIT checklist item numbers. The order of the items has been modified to group similar items (see http://www.equator-network.org/reporting-guidelines/spirit-2013-statement-defining-standard-protocol-items-for-clinical-trials/). Title {1}Infant Reflux Trial: study protocol for a multicentre randomized controlled trial on the treatment of gastroesophageal reflux disease in infantsTrial registration {2a and 2b}ClinicalTrials.gov ID NCT06255886, February 13, 2024EU-CT 2022–502770-16-00Protocol version {3}November 4, 2024.

Protocol version 5Funding {4}This is a noncommercial study supported by the following:Material and running costs: The Fund to Support Independent, Strategic Clinical Research in the Region of Southern Denmark, the Knud and Edith Eriksen’s Memorial Foundation, and Fabrikant Mads Clausen Foundation, Danfoss.Xeolas Pharmaceuticals will provide the placebo and the PPI, and Nestlé Health Science will provide extensively hydrolysed formula, Althéra HMOScholarships:The Fund to Support Clinical Doctoral Candidates in the Region of Southern DenmarkThe Department of Regional Health Research, University of Southern DenmarkHospital SønderjyllandAuthor details {5a}1. Pediatric Department, University Hospital of Southern Denmark, Kresten Philipsens Vej 15, 6200 Aabenraa and Department of Regional Health Research, University of Southern Denmark, Campusvej 55, 5230 Odense, DenmarkORCID ID: 0000-0001-5569-3439Corresponding author: Natalia.Barkholt@rsyd.dk2. Paediatric Clinic by Dr.

Kasper Dalby, Slotsgade 20 C, 5000 Odense, Denmark3. Research Unit of Emergency Medicine, University Hospital of Southern Denmark, Kresten Philipsens Vej 15, 6200 Aabenraa and Department of Regional Health Research, University of Southern Denmark, Campusvej 55, 5230 Odense, Denmark4. Hans Christian Andersen Children's Hospital, Odense University Hospital, Kløvervænget 23 C, 5000 Odense and University of Southern Denmark, Campusvej 55, 5230 Odense, Denmark5.

Hans Christian Andersen Children's Hospital, Odense University Hospital, Kløvervænget 23 C, 5000 Odense, and University of Southern Denmark, Campusvej 55, 5230 Odense, Denmark.Name and contact information for the trial sponsor {5b}Gitte Zachariassen, ProfessorPhone Number: +4565413809E-mail: Gitte.Zachariassen@rsyd.dkRole of sponsor {5c}The sponsor contributed to all phases in the study, including study design, protocol development, and implementation in a clinical setting. The sponsor will be involved in the study management, data interpretation, and writing and publishing the final report.The study findings will be published regardless of the study results.

Introduction

Background and rationale {6a}

Gastroesophageal reflux (GER) is a common condition in infants and is defined as the “passage of gastric contents into the esophagus with regurgitation or vomiting” in otherwise healthy infants [1]. Around 50% of infants younger than 4 months of age have frequent regurgitation episodes [2]. In most cases, it is a harmless, self-limiting condition, and in 90% of cases, symptoms diminish before 12 months of age [1–5].

Gastroesophageal reflux disease (GERD) is defined as GER and “persistent troublesome symptoms or complications” according to the international consensus statement [1] published in the updated clinical practice guidelines from NASPGHAN and ESPGHAN (2018). Troublesome symptoms may include failure to thrive, back arching, food refusal, regurgitation, and irritability. GERD also causes significant parental distress, loss of workdays [6], and a problematic start to parenthood.

The prevalence of GERD varies across different studies, ranging from 23% to 40% [4].

GERD is a clinical diagnosis based on the examination of the infant and the parents’ reports of the infant’s symptoms. There is no evidence to support the routine use of endoscopy and pH measurements to confirm the diagnosis unless symptoms are refractory to medical treatment [1].

Proton-pump inhibitors (PPI) have been recommended as first-line therapy in infants with GERD [7]. However, paediatricians have been concerned that too many infants are unnecessarily treated with PPI [8], and recent studies have questioned the efficacy of PPI in infants [4, 9]. There are only a few randomized studies investigating PPI treatment in infants < 1 year of age, and most of these studies do not show a significant effect [4, 9, 10].

Furthermore, several side effects of PPI have been reported. Up to 10% of infants experience gastrointestinal tract symptoms, such as stomach pain, nausea, and constipation. PPI treatment increases the susceptibility to both gastrointestinal and respiratory infections [11–13] and may have long-term side effects, including an increased risk of developing allergies, coeliac disease, and bone fractures [11, 12], as well as poor nutrient absorption [4, 11, 14–17].

Allergy to cow’s milk protein (CMP) is the most common food allergy in early childhood, with an estimated prevalence of 0.5–3% [18], and presents with various symptoms predominantly from the skin and gastrointestinal tract including regurgitation and vomiting [19]. Symptoms of GERD can be difficult to distinguish from those of allergy to CMP. CMP allergy is an immune reaction that can be either IgE-mediated, presenting with immediate type-1 reactions, or non-IgE-mediated, with delayed symptoms [18–20].

The latter is probably the most common in infants [21]. GERD may be a manifestation of allergy to CMP, or ingestion of cow’s milk may induce a non-immunologic mechanism, aggravating GERD symptoms. A reliable diagnosis of CMP allergy can only be based on an oral food challenge (OFC) with milk preceded by a CMP-elimination period.

Thus, guidelines from NASPGHAN and ESPGAN [1] and a recent position paper from ESPGHAN [19] recommend that infants with GERD undergo a 2–4-week CMP-elimination diet before treatment with PPI is considered. The evidence for an effect of a CMP-free diet in infants diagnosed with GERD is scarce.

Objectives {7}

This study aims to assess the efficacy of GERD treatments in infants below 1 year of age, comparing a CMP-free diet or PPI with a control group receiving placebo PPI medication. Both the PPI group and the control group will receive a diet containing CMP. The efficacy of the treatment will be evaluated based on a reduction in regurgitation episodes during a f4our-week study period.

In addition, the possibility that GERD is a manifestation of allergy to cow’s milk will be investigated by measuring specific IgE against CMP and performing an OFC with cow’s milk in infants who improve on the CMP-free diet. We hypothesize that a CMP-free diet is more efficient than PPI in treating symptoms of GERD in infants.

Trial design {8}

This is an investigator-initiated superiority trial, designed as a multicentre, parallel-group, randomized controlled trial with two active groups and a control group receiving placebo medication. The diet group is not blinded to the intervention due to practical reasons, whereas the PPI and placebo groups are blinded for both parents and healthcare professionals. The allocation will be concealed for all three groups during the analysis process.

The 4-week intervention duration is considered sufficient to observe an effect of the dietary treatment but short enough to minimize the influence of natural improvement in GERD symptoms with increasing age.

Patient involvement in trial design

Parents of infants with GERD have been involved in developing the study design and information sheets and have tested the application that will be used to register GERD symptoms in the trial. Potential barriers have been identified to improve adherence to the intervention.

Methods: participants, interventions, and outcomes

Study setting {9}

Patients will be recruited from a university hospital, a regional hospital, and a paediatric clinic in the region of Southern Denmark. A complete list of the study sites can be obtained at the Clinical Information System (CTIS): https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2022-502770-16-00.

Eligibility criteria {10}

Ninety-six infants will be recruited equally from the three centres. Qualified physicians will recruit participants by screening potential candidates to ensure they meet the study’s inclusion criteria. At the time of inclusion, infants must be between 1 month and 1 year of age and meet the diagnostic criteria for GERD.

Participants must have an average of at least three regurgitation episodes per day and present at least one of the following troublesome symptoms: failure to gain weight (decrease in z-score according to a reference), crying, irritability, refusing the breast/bottle despite hunger, breathing pauses/apnoea, or back arching.

The exclusion criteria include infants who have diagnosed or suspected syndromes or genetic disorders, major congenital anomalies, metabolic or other serious diseases, a history of abdominal surgery, a diagnosed allergy to CMP, or have been treated with a CMP-free diet or PPI within the last week before the initial consultation (Fig. 1).Fig. 1Flow of participants and data collection in the Infant Reflux Trial

Who will take informed consent? {26a}

Informed consent will be obtained by the physician who diagnoses the infant with GERD. Clear and comprehensive oral information about the study will be provided in a room free from disturbances, along with written information. Parents will have time to consider participation before signing the consent form.

Additional consent provisions for collection and use of participant data and biological specimens {26b}

Not applicable. No additional consent will be collected, and no biological specimens will be stored.

Interventions

Explanation for the choice of comparators {6b}

In Denmark, the standard practice for treating GERD in infants is a 2–4-week CMP-free diet, followed by PPI therapy if the diet proves ineffective. This study aims to compare these treatments with a control group. This is a low-intervention study, utilizing only authorized products.

Intervention description {11a}

In the first week after inclusion, the parents will register the number of daily visibly observable regurgitation episodes without treatment (run-in) in a mobile application (MyCap app). After the run-in period, participants will be randomly allocated to one of three groups: CMP-free diet, treatment with PPI, or placebo PPI (control group).In the diet group, the infant’s diet will be modified to eliminate CMP. If the infant is breastfed, the mother will follow a CMP-free diet while continuing to breastfeed.

Formula-fed infants will receive an extensively hydrolysed formula.In the PPI group, the infant will be treated with an oral solution of omeprazole in doses of 1 mg/kg per day and continue a diet containing CMP.In the control group, the infant will receive a placebo PPI mixture, produced and packaged to be indistinguishable from the PPI, and continue a diet containing CMP.

Symptoms will be registered in the application during the 4 weeks of intervention. Parents will be provided with the PPI/placebo medication/hydrolysed formula according to randomization. The infant will be examined at the end of treatment, and a blood sample will be collected.

Infants who responded positively to the dietary intervention will undergo an OFC with milk.

Criteria for discontinuing or modifying allocated interventions {11b}

Breastfed infants in the diet intervention group, whose mothers are unable to maintain a CMP-free diet and experience more than four dietary breaches per week involving visible milk, will be withdrawn from the study.

Formula-fed infants, who cannot tolerate the hypoallergenic formula after 3–4 days of attempted transition, will also be withdrawn from the study. Reasons for withdrawal will be documented.

Collected data from patients who drop out of the study will be used until the date when consent is withdrawn.

Strategies to improve adherence to interventions {11c}

Focusing on rapid inclusion after referral will be essential to eliminate waiting time and avoid the difficulties associated with recruitment and dropout rates. Parents will have the opportunity to contact the research team throughout the study period to ensure adherence to the intervention. Number and type of contacts will be registered in the REDCap database.

A daily notification from the application will remind the parents to register the primary outcome.

Relevant concomitant care permitted or prohibited during the trial {11d}

In the event of any treatment for intercurrent illnesses, such as constipation or asthma, the substance used will be registered in the study records.

Provisions for posttrial care {30}

No provisions for posttrial care are planned. After the trial, the participants will receive standard care provided by the health care system. Infants with newly identified CMP allergy will be referred to follow-up by a paediatric allergist, according to the local guidelines.

Any late adverse reactions to PPI will be reported in accordance with standard procedures (not a part of this trial).

Outcomes {12}

Primary outcome

The primary outcome is the reduction of regurgitation episodes in the fourth week of active treatment with either extensively hydrolysed hypoallergenic infant formula or PPI, compared with placebo. The parents will be responsible for registering the daily number of regurgitation episodes in the MyCap app throughout the treatment period (Tables 1 and 2). Table 1Primary and secondary outcome measuresOutcome measureDescriptionTimelinePrimaryParent-reported reduction in regurgitation episodes in the fourth week of treatment (compared with the run-in period) in both the diet and the PPI group, compared with the control group receiving placebo medicationAssessed at follow-up after 4 weeks of treatmentSecondaryReduction in the number of regurgitation episodes (compared with the run-in period) in the diet group compared with the PPI groupAssessed at follow-up after 4 weeks of treatmentChange in body weight (z-scores according to a reference)Assessed at follow-up after 4 weeks of treatmentParent-reported GERD-related symptoms, compared to symptoms before the start of treatment, recorded in the applicationFollow-up after 4 weeks of treatmentNumber of infants with GERD with positive specific IgE for cow’s milk protein (values above 0.35 kU/l are considered positive).

The blood test result is compared with the effect of the treatment and the outcome of the milk challengeAfter 4 weeksResult of the milk challenge test in all infants in the diet groupAfter the 4-week intervention study is completedAdverse effects of trial medication or dietReported weekly, assessed after 4 weeks of treatmentTable 2Parent-reported symptoms registered in the application formDaily registrations• The volume of regurgitation• Frequency of meal-related discomfort episodes• Crying within 5 min after feeding• Refusal of breast or bottleWeekly registrations• The presence of blood-tinged regurgitation or vomit• Short pauses in breathing• Episodes of pallor or cyanosis in the face or lips• Episodes of troublesome breathing or coughing

Secondary outcomes

Several secondary outcomes will be registered throughout the study (Table 1). The reduction in the weekly number of regurgitation episodes in the diet group will be compared to the PPI group to determine the most effective treatment.

Parents are asked to register a wider range of GERD-related symptoms described in Table 2. After 4 weeks of active treatment, growth parameters are measured and compared to baseline. IgE levels for CMP are measured in a blood sample (finger prick).

Values above 0.35 kU/l are considered positive. Adverse events are reported weekly by parents through the application.

After a 4-week intervention period, infants in the diet group who responded to a CMP-free diet will have an in-hospital OFC with cow’s milk protein-based formula. During the test, the infants will receive increasing doses of cow’s milk every 30 min, reaching a cumulative dose of 200 ml. A nurse will record immediate symptoms, while the parent(s) monitor and report any late symptoms at home, informing the nurse by phone within 48 h.

The proportion of infants with a positive OFC and a positive IgE against CMP will be compared with those who have a positive OFC but a negative specific IgE against CMP.

Participant timeline {13}

Participant timeline

Sample size {14}

A sample size calculation has been performed on the primary outcome. The calculation is based on an estimated baseline frequency of 50 regurgitation episodes per week prior to treatment initiation and a minimal clinically significant difference of 12 regurgitation episodes per week (or 24% reduction). These assumptions are based on the best clinical estimation derived from clinical experience.

Due to the short duration of the trial, it is assumed that the treatment’s effect is not influenced by time. To achieve a strength of 80% and an alpha error of 2.5% (adjusted for repeated testing), 25 infants are required in each of the three arms. To account for a potential 20% drop-off, 32 subjects will be included in each arm.

Secondary outcomes will be analysed descriptively, as the study is not designed to provide statistical power for these endpoints.

Recruitment {15}

The physician will recruit patients upon diagnosis of GERD, with recruitment primarily occurring from the outpatient clinic setting but also in some cases from an inpatient ward.

To reduce inter-site variability in recruitment across this multicentre study, all sites receive standardized on-site training in the study protocol (diagnosis, inclusion and exclusion criteria, consent, and data collection).

The number of eligible infants in the region was assessed prior to the study (in 2021), indicating that the target sample size is achievable within the planned recruitment period.

The study is designed as a multicentre study to enhance the number of patients, and we plan to recruit 2–3 patients per month at each centre within 14 months. If necessary, another regional hospital will be included in the study.

Easily accessible study materials will be handed out at first visit. The materials have been developed with input from parents who have infants with GERD.

Assignment of interventions: allocation

Sequence generation {16a}

An external data manager, not involved in interpreting the data, created a computer-generated randomization sequence in REDCap prior to recruitment. The sequence was generated with random block sizes and stratified by site and age above/below 4 months of age at inclusion.

When participants are enrolled in the study, they are randomly allocated in the online randomization tool (REDCap) by a local research team member. Each participant receives an individual code.

Concealment mechanism {16b}

The randomization codes for participants in the diet group are not concealed, and the parents are informed about the dietary treatment at allocation (t2, Fig. 2). In contrast, the allocation sequence in the PPI and control group is concealed from the sponsor, all investigators, healthcare workers, and parents throughout the 4-week treatment period.Fig.

2SPIRIT figure showing the schedule of enrolment, interventions, and assessments*Cow’s milk-free diet is given to the mother if the infant is breastfed. An extensively hydrolysed hypoallergenic formula is used if the infant is formula-fed. **Placebo medicine is identical to PPI in appearance, taste, and texture. Blinded project nurses will hand out the trial medication according to the randomization code

The PPI and placebo mixture are produced by the same pharmaceutical company and will be indistinguishable in appearance, taste, and texture.

Data analyst will be blinded for all interventions throughout the entire study period.

Implementation {16c}

The study will be implemented in a phased approach, starting with a small centre in the initial months before being expanded to a larger setting. This approach aims to gather practical insights and optimize procedures to minimize the risk of unforeseen challenges in a real-world setting.

Assignment of interventions: blinding

Who will be blinded {17a}

Participants, investigators, healthcare personnel, and the statistical analyst will be blinded to the medical allocation (PPI or placebo), but the diet group cannot be blinded.

Procedure for unblinding if needed {17b}

If unblinding of a participant becomes necessary during the study, a secure electronic unblinding procedure will be available 24 h a day. The Hospital Pharmacy at Odense University Hospital holds a copy of the randomization list.

Data collection and management

Plans for assessment and collection of outcomes {18a}

The parents will register daily symptoms in the application. Anthropometrics will be measured at the first visit and at the end of treatment. The blood sample results (IgE against CMP) and OFC with milk will also be registered.

Figures 1 and 2 describe enrolment, intervention, and data collection steps.

Plans to promote participant retention and complete follow-up {18b}

Clear communication and personalized support will help address any concerns throughout the study, thereby minimizing dropouts. Fast track to the first appointment and flexible follow-up scheduling will ensure convenience and reduce participant burden, encouraging continued engagement. No compensation will be given for travel or time, but free parking at the hospital is offered.

Data management [11]

All data collected from the application and hospital records will be registered in an online REDCap database. A range check will be applied to all important fields in the application and the database to ensure the accuracy of the data. The database is hosted and securely stored by Open Patient data Explorative Network (OPEN) in Odense, a regional organization in Southern Denmark (ref.: Structure and growth of a Danish research infrastructure and support unit for health research — OPEN (Open Patient data Explorative Network), Katrine Hass Rubin et al., BMC Health Services Research, volume 25, article number: 753 (2025)).

Confidentiality {27}

Participant confidentiality will be strictly maintained throughout the trial in compliance with Danish data protection laws and GDPR. Personally identifiable information will be securely stored in systems supported by the Region of Southern Denmark. Only authorized personnel will access identifiable data; no personal information will be included in reports or publications.

Any data breach will be promptly reported. Data will be securely stored after the study is completed according to regulatory requirements.

Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in this trial/future use {33}

This is not applicable. The study does not involve the collection or storage of genetic or molecular specimens for this study or future use.

Statistical methods

Statistical methods for primary and secondary outcomes {20a}

The outcome will be evaluated in the three groups, from baseline registration to weeks 1–4, using a mixed Poisson model. The significance level will be set at a p-value of 0.025 to allow multiple comparisons. The p-value will be based on the 4-week estimate, as this is the primary endpoint of interest.

Effect estimates will be reported together with their 95% confidence intervals. Marginal means will be presented together with their 95% confidence intervals for each of the time points to assess the entry of an effect over time (secondary outcome). Weight z-scores will be calculated according to World Health Organization (WHO) growth reference (0–5 years) [22].

The model fit will be assessed via residual plots and the inspection of the dispersion parameter. Should the model yield an unsatisfactory fit, a generalized Poisson model or a linear model will be considered in further analysis.

An intention-to-treat analysis approach will be employed, and mixed models will be used to analyse the data, thereby minimizing the potential risk of attrition bias. All analyses are described in a statistical analysis plan in the study protocol.

Interim analyses {21b}

An interim analysis will be conducted by an independent statistician after enrolment of 50% of the participants to ensure participant safety while maintaining blinding for the research team. The stopping criterion is a significant weight loss in the control group compared to the intervention group. In this case, the study will be converted to an open-label, two-armed study without a control group.

The sponsor and the investigators will make this decision.

Methods for additional analyses (e.g. subgroup analyses) {20b}

Exploratory subgroup analysis will be performed on the effect in participants with improvement in symptoms after the CMP elimination diet, to assess whether the response pattern differs between the breastfed group and the bottle-fed group.

Methods in analysis to handle protocol non-adherence and any statistical methods to handle missing data {20c}

The mixed Poisson model enables the evaluation of progression over time and efficiently handles missing values, assuming missing observations are missing at random. If data are missing and are not at random, a joint modelling approach will be applied to reduce bias.

Multiple imputation will be performed if missing exceeds 20%. This threshold corresponds to the 20% expected dropout rate in the sample size calculation.

Plans to give access to the full protocol, participant-level data, and statistical code {31c}

The full protocol is available on Clinical Trials Information System (CTIS), but the participant dataset and statistical coding will not be shared. De-identified data may only be shared upon specific request and following approval in accordance with Danish law.

Oversight and monitoring

Composition of the coordinating centre and trial steering committee {5d}

The trial steering committee is composed of the sponsor, the principal investigator, and the local investigators. The trial steering committee will meet every second month.

The sponsor at Odense University Hospital will be responsible for the overall trial management. The principal investigator will be responsible for the communication and coordination between the study sites and the data management. The local investigators at each centre will be responsible for ensuring that the trial is conducted in accordance with the protocol, including obtaining informed consent, ensuring accurate data collection, and reporting to the Trial Steering Committee.

Composition of the data monitoring committee and its role and reporting structure {21a}

This is not applicable. A formal data monitoring committee will not be established due to the nature and scale of the study, which does not involve high-risk interventions or significant safety concerns. Instead, the research team will ensure monitoring and adherence to the protocol and ethical standards (see the “Frequency and plans for auditing trial conduct {23}” section).

Adverse event reporting and harms {22}

The study is a low-intervention study, as only authorized products are being used. As a result, only serious unexpected serious reactions (SUSARs) will be reported, while routine or expected adverse events will not be reported. The Summary of Product Characteristics from Xeolas Pharmaceuticals will be used as a reference.

SUSARs must be reported to the coordinating investigator and the sponsor within 24 h after a local investigator becomes aware of the event. Potentially fatal SUSARs must be reported to the EudraVigilance database as soon as possible and at the latest, within 7 days. Other SUSARs will be reported within 15 days after the sponsor has become aware of the event.

Frequency and plans for auditing trial conduct {23}

External monitoring of the study will be conducted by the unit for Good Clinical Practice (GCP) at OPEN in Odense, Denmark, which will manage the clinical trial audit in accordance with standard procedures. This unit is independent of both the sponsor and the investigators. A monitoring plan has been established.

Monitoring of protocol adherence and data quality will be conducted after inclusion of the first three patients at each centre and for 10% of all participants at each site. More details can be found on the GCP website: https://gcp-enhed.dk/english/.

Plans for communicating important protocol amendments to relevant parties (e.g. trial participants and ethical committees) {25}

Important protocol amendments will be submitted for approval to the ethical committee and other relevant authorities. Once approved and if relevant, the amendments will be promptly communicated to all parties involved in the study, including the research team, collaborators, the hospital pharmacy, and study participants.

Dissemination plans {31a}

The principal investigator and the sponsor will report the results in CTIS, no later than 1 year after the trial is completed. The findings of this study will be disseminated through publication in an international, peer-reviewed, scientific journal and presentation at relevant conferences. Patient-friendly material will be distributed to the public and relevant parties in primary care.

Discussion

GERD is a prevalent condition in infancy, with at least a quarter of infants (0–18 months) experiencing symptoms daily [5]. This causes parental concern and multiple health care visits and places considerable burden on the healthcare system based on unpublished internal data from our department. Diagnosing and treating GERD in infants are challenging, as the diagnostic criteria can be difficult to interpret, and the evidence supporting treatment options is weak.

The parents are often frustrated and pleading for treatment to calm their uncomfortable child, which may be one of the reasons for the rise in PPI prescriptions in Denmark over the past decade, with 3% of all infants being prescribed PPI in 2018 [4]. Recent reviews [4, 9, 10] conclude that medical treatment with PPI is as effective as a placebo in infants, but the results are based on a limited number of studies. There are several side effects of GERD treatment, and the consequences of the antacidic impact on the intestinal microbiota [14] are unknown.

Therefore, a better understanding of GERD treatment in infants is needed.

This study is pivotal, as no existing studies have compared cow’s milk-free diet to PPI in infants with GERD [10]. By adding the control group to this study, we can further target the placebo effect of the PPI, which has been observed in other studies [9].

The major strengths of the trial include its design as a randomized, placebo-controlled study and the involvement of parents to ensure that the application is applicable to parents’ daily life with infants experiencing troublesome symptoms. The application enables easy daily registration of outcomes, providing valuable information about symptoms throughout the treatment. This novel method of symptom registration is designed to prevent recall bias.

Previous studies demonstrate a significant heterogeneity in outcome measures [9, 23], with many relying on symptom scores based on parent-reported symptoms, such as crying and irritability, which are largely subjective observations. To minimize the risk of reporting bias and to avoid confusion with colic and the term “silent reflux”, we have chosen the primary outcome to be the reduction in the number of regurgitation episodes, defined as episodes with visible regurgitation or vomiting. This measure is the most objective, as the parents can numerically count it.

To ensure consistent reporting, parents will be instructed on the reporting procedure at the time of enrolment.

The main limitation of this study is that most outcomes rely on parent-reported observations, which may be influenced by parental perception, expectations, and context. This can limit the generalizability to other populations with different cultural or educational backgrounds.

Another limitation is the lack of blinding in the dietary arm, as it is not possible to blind the breastfeeding women’s dietary intake. The lack of concealment of the intervention may influence the parental behaviour and report of symptoms, particularly if parents preferred allocation to the medication group. Similarly, mothers in the medication group may consciously or unconsciously change their own diet or their infant’s diet, introducing a risk of performance bias.

Blinding of the outcome assessor and use of reporting guidelines (CONSORT) will lower the risk of reporting bias. One important consideration is the natural remission of GERD in infants over time, which may complicate the interpretation of the results. To minimize this risk, the intervention is limited to a duration of 4 weeks.

The period between 1 month and 12 months of age is a critical stage in infant development, marked by significant changes. Although it would have been interesting to investigate a narrower age range, such as < 6 months of age, a broader age range was selected to align with the current clinical guidelines for GERD. However, we plan to include sub-analyses of the different age groups.

The use of different formulas to treat formula-fed infants diagnosed with GERD has been discussed, and an extensively hydrolysed formula was chosen for this study over an amino-based product due to taste acceptance [24].

Ethical considerations have been of great importance in designing this intervention study, as the treatment involves infants. The emphasis has been on minimizing infants’ discomfort throughout the study.

In conclusion, GERD affects many infants and their families and can significantly impact infants’ health and well-being, but the evidence supporting current treatment is weak. Therefore, it is essential to gain a deeper understanding of this condition and to evaluate treatments through a randomized controlled trial. This study addresses an urgent knowledge gap and can contribute to a more evidence-based approach to the treatment, which is needed in daily clinical practice.

Trial status

CTIS protocol version is number 5. Recruitment started on October 27, 2025, with anticipated completion within 14 months.

Related articles

PubMed

Hiatal Hernia and Conclusive Gastroesophageal Reflux Disease: Size Matters.

Background/Aims The Lyon Consensus considers hiatal hernia (HH) as a supportive metric for the diagnosis of gastroesophageal reflux disease (GERD) when evidence is inconclusive; however, HH size is not taken into consideration. We aimed to correlate HH size with conclusive evidence of GERD from multichannel intraluminal impedance and pH monitoring (MII-pH) and upper endoscopy. Methods We analyzed a retrospective consecutive cohort of patients with suspected GERD with and without HH on high-re...

PLOS

Healthy lifestyle as a protective factor against the risk of gastroesophageal reflux disease: Prospective population cohort analysis

Background: Lifestyle modifications are recommended by American Gastroenterological Association (AGA) for managing gastroesophageal reflux disease (GERD), a significant health issue; but evidence is scarce. This study aims to investigate the longitudinal association between healthy lifestyle behaviors and the risk of GERD. Methods: We analyzed data from 306,543 participants aged between 38 and 73 years without GERD at baseline from the UK Biobank. A summarized healthy lifestyle score (range, 0–7...